Thousands of bottles of a widely prescribed blood pressure medication are being pulled from pharmacy shelves across the United States. The nationwide recall was initiated due to a manufacturing defect that could significantly compromise the medication’s effectiveness, leaving patients vulnerable to poorly managed hypertension.
According to an official announcement by the U.S. Food and Drug Administration (FDA), the recall impacts more than 11,400 bottles of prescription chlorthalidone tablets. Because managing high blood pressure requires consistent and reliable medication performance, health officials are urging patients to check their prescription labels immediately.
The Details Behind the Recall
The voluntary recall was formally set in motion on June 5 by Inventia Healthcare Limited, an India-based pharmaceutical manufacturer headquartered in Mumbai. The impacted product is the 25-mg dosage strength of chlorthalidone tablets. While Inventia Healthcare Limited manufactured the medication, the drug was distributed throughout the United States by New Jersey-based distributor Rising Pharma Holdings, Inc.
The recall encompasses both 100-count and 1,000-count prescription bottles, totaling approximately 11,460 bottles in circulation nationwide.
Following an analysis of the situation, the FDA officially classified the incident as a Class II recall on June 22. By definition, the FDA categorizes a Class II recall as a moderate hazard situation where exposure to or use of the violating product could trigger temporary or medically reversible adverse health consequences. While the immediate risk of severe or life-threatening injury is low, the potential failure of the drug to manage a chronic condition like high blood pressure presents a distinct medical concern.
Why the Medication is Being Pulled
The recall was triggered after routine quality control testing revealed a critical flaw in how the pills behave. Specifically, the FDA noted that the affected lots “failed dissolution specifications.”
What does “failed dissolution” mean? When a tablet fails dissolution testing, it means the pill does not break down or dissolve within the human body at the rate or consistency required. If a pill cannot dissolve properly in the digestive tract, the body cannot absorb the active pharmaceutical ingredient as intended. Consequently, patients taking the medication may receive a sub-therapeutic dose, rendering the drug largely ineffective at controlling their medical condition.
What is Chlorthalidone?
Chlorthalidone is a widely utilized prescription diuretic—often referred to as a “water pill”—that plays a foundational role in cardiovascular health. It is primarily prescribed to manage hypertension (high blood pressure) and to treat edema, a condition characterized by fluid retention in the body’s tissues.
The drug functions by stimulating the kidneys to filter out excess water and sodium from the bloodstream, which is then eliminated through urine. By reducing the overall volume of fluid circulating through the blood vessels, chlorthalidone successfully lowers blood pressure and diminishes the workload placed on the heart. When the drug fails to dissolve properly, blood pressure can spike unnoticed, increasing long-term cardiovascular risks.
A Pattern of Cardiovascular Drug Disruptions
This incident marks the second major recall involving a common blood pressure medication in a relatively short timeframe. Less than a year prior, the pharmaceutical market faced an even larger disruption.
In October 2025, more than 500,000 bottles of prazosin hydrochloride—another frequently prescribed medication used to treat high blood pressure—were recalled nationwide. That massive recall was sparked by an entirely different issue: concerns that the capsules were contaminated with unsafe levels of nitrosamines, which are chemical impurities classified as potential human carcinogens. While the underlying causes of the two recalls differ, both events underscore ongoing challenges in global pharmaceutical manufacturing and quality control.
Essential Next Steps for Patients
At this time, the FDA has not issued specific, step-by-step instructions directly to consumers regarding how to return the product. However, medical experts and regulatory bodies emphasize that patients should take proactive steps to safeguard their health:
- Inspect Your Bottle: If you take 25-mg chlorthalidone tablets, examine the prescription label closely. Look for the manufacturer’s name (Inventia Healthcare Limited), the distributor (Rising Pharma Holdings, Inc.), and cross-reference the National Drug Code (NDC) and batch numbers.
- Consult Your Pharmacist or Doctor: If you find that your medication matches the recalled lots, contact your pharmacy or healthcare provider immediately to arrange for a safe replacement.
- Do Not Abruptly Stop Treatment: The American Heart Association strongly warns against suddenly stopping any blood pressure medication without professional guidance. Abruptly discontinuing antihypertensive drugs can cause a dangerous rebound spike in blood pressure, leading to severe health complications. Keep taking your current pills until your doctor or pharmacist provides an alternative prescription.